These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 26528783)
1. Biosafety Oversight and Compliance: What do you Mean, I have to Fill Out Another Form?! Petrella BL Curr Protoc Microbiol; 2015 Nov; 39():1A.5.1-1A.5.16. PubMed ID: 26528783 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of the role and effectiveness of institutional biosafety committees in providing oversight and security at biocontainment laboratories. Race MS; Hammond E Biosecur Bioterror; 2008 Mar; 6(1):19-35. PubMed ID: 18386970 [TBL] [Abstract][Full Text] [Related]
3. Biosafety and biosecurity measures: management of biosafety level 3 facilities. Zaki AN Int J Antimicrob Agents; 2010 Nov; 36 Suppl 1():S70-4. PubMed ID: 20801002 [TBL] [Abstract][Full Text] [Related]
4. Characterization of Departures from Regulatory Requirements Identified During Inspections Conducted by the US Federal Select Agent Program, 2014-15. Bjork A; Sosin DM Health Secur; 2017; 15(6):587-598. PubMed ID: 29193983 [TBL] [Abstract][Full Text] [Related]
5. Institutional biosafety committees and public participation: assessing an experiment. Dutton DB; Hochheimer JL Nature; 1982 May; 297(5861):11-5. PubMed ID: 7070528 [TBL] [Abstract][Full Text] [Related]
6. Biosafety in research: oversight and basic principles. Whetstone C; Nelson BJ; Woods CR Pediatr Infect Dis J; 2010 Aug; 29(8):763-5. PubMed ID: 20661104 [No Abstract] [Full Text] [Related]
7. The Evolving Landscape of Institutional Biosafety Committees and Biosafety Programs: Results from a National Survey on Organizational Structure, Resources, and Practices. Johnson CM; Dobos KM Appl Biosaf; 2019 Dec; 24(4):213-219. PubMed ID: 36032060 [TBL] [Abstract][Full Text] [Related]
8. Biosafety Level 3 setup for multiphoton microscopy in vivo. Barlerin D; Bessière G; Domingues J; Schuette M; Feuillet C; Peixoto A Sci Rep; 2017 Apr; 7(1):571. PubMed ID: 28373723 [TBL] [Abstract][Full Text] [Related]
9. American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281 [TBL] [Abstract][Full Text] [Related]
10. The National Institutes of Health system for enhancing the science, safety, and ethics of recombinant DNA research. Shipp AC; Patterson AP Comp Med; 2003 Apr; 53(2):159-64. PubMed ID: 12784849 [TBL] [Abstract][Full Text] [Related]
11. The Main Biological Hazards in Animal Biosafety Level 2 Facilities and Strategies for Control. Li XY; Xue KN; Jiang JS; Lu XC Biomed Environ Sci; 2016 Apr; 29(4):300-4. PubMed ID: 27241742 [TBL] [Abstract][Full Text] [Related]
12. A primer on the requirements for select agents and toxins used in biomedical and agricultural research applications. Johnston TP Health Phys; 2006 May; 90(5 Suppl):S56-61. PubMed ID: 16607169 [TBL] [Abstract][Full Text] [Related]
15. Development of the National Institutes of Health Guidelines for Recombinant DNA Research. Talbot B Public Health Rep; 1983; 98(4):361-8. PubMed ID: 6611823 [TBL] [Abstract][Full Text] [Related]
16. Bridging biosafety and biosecurity gaps: DURC and ePPP policy insights from U.S. institutions. Gillum DR; Tran A; Fletcher J; Vogel KM Front Bioeng Biotechnol; 2024; 12():1476527. PubMed ID: 39398640 [TBL] [Abstract][Full Text] [Related]
17. Lessons to be Learned from Recent Biosafety Incidents in the United States. Weiss S; Yitzhaki S; Shapira SC Isr Med Assoc J; 2015 May; 17(5):269-73. PubMed ID: 26137650 [TBL] [Abstract][Full Text] [Related]
18. The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment. Shurtleff AC; Garza N; Lackemeyer M; Carrion R; Griffiths A; Patterson J; Edwin SS; Bavari S Viruses; 2012 Dec; 4(12):3932-51. PubMed ID: 23342380 [TBL] [Abstract][Full Text] [Related]